Module 1 2021

Challenges for economic modelling  External validity  Trial outcomes / surrogate endpoints  Appropriate comparators (and are these country specific)  Head to head / indirect comparison  Appropriate populations / subpopulations Trials may meet regulatory requirements but not be suitable for clinicians or funders.

53

Trial Outcomes

 Is the outcome clinically significant  Does the trial have secondary endpoints  Are the (statistically significant) secondary endpoints clinically significant

54

27